Jonathan Duffy1, Peter Johnsen2, Mary Ferris3, Mary Miller3, Kevin Leighton2, Mark McGilvray3, Lucy McNamara4, Lucy Breakwell4, Yon Yu5, Tina Bhavsar5, Elizabeth Briere4, Manisha Patel4. 1. a Immunization Safety Office, Centers for Disease Control and Prevention , Atlanta , Georgia, USA. 2. b University Health Services, Princeton University , Princeton , New Jersey , USA. 3. c Student Health Service , University of California Santa Barbara , Santa Barbara , California , USA. 4. d Meningitis and Vaccine-Preventable Diseases Branch , Centers for Disease Control and Prevention , Atlanta , Georgia , USA. 5. e Regulatory Affairs, Office of the Director , National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention , Atlanta , Georgia , USA.
Abstract
OBJECTIVE: To assess the safety of meningococcal group B (MenB)-4C vaccine. PARTICIPANTS: Undergraduates, dormitory residents, and persons with high-risk medical conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 12/2013 through 11/2014. METHODS: Adverse events (AEs) were identified by 15 minutes of observation postvaccination, spontaneous reports, surveys, and hospital surveillance. Causality was assessed for serious adverse events (SAEs). RESULTS: 16,974 persons received 31,313 MenB-4C doses. The incidence of syncope during the 15-minutes post-dose 1 was 0.88/1000 persons. 2% of participants spontaneously reported an AE (most common were arm pain and fever). 3 SAEs were suspected of being caused by the vaccine, including one case of anaphylaxis. CONCLUSIONS: Most AEs reported were nonserious and consistent with previous clinical trial findings. Measures to prevent injury from syncope and to treat anaphylaxis should be available wherever vaccines are administered. Our safety evaluation supports the use of MenB-4C in response to outbreaks.
OBJECTIVE: To assess the safety of meningococcal group B (MenB)-4C vaccine. PARTICIPANTS: Undergraduates, dormitory residents, and persons with high-risk medical conditions received the MenB-4C vaccine two-dose series during mass vaccination clinics from 12/2013 through 11/2014. METHODS: Adverse events (AEs) were identified by 15 minutes of observation postvaccination, spontaneous reports, surveys, and hospital surveillance. Causality was assessed for serious adverse events (SAEs). RESULTS: 16,974 persons received 31,313 MenB-4C doses. The incidence of syncope during the 15-minutes post-dose 1 was 0.88/1000 persons. 2% of participants spontaneously reported an AE (most common were arm pain and fever). 3 SAEs were suspected of being caused by the vaccine, including one case of anaphylaxis. CONCLUSIONS: Most AEs reported were nonserious and consistent with previous clinical trial findings. Measures to prevent injury from syncope and to treat anaphylaxis should be available wherever vaccines are administered. Our safety evaluation supports the use of MenB-4C in response to outbreaks.
Authors: Sarah A Mbaeyi; Catherine H Bozio; Jonathan Duffy; Lorry G Rubin; Susan Hariri; David S Stephens; Jessica R MacNeil Journal: MMWR Recomm Rep Date: 2020-09-25
Authors: Silvia Perez-Vilar; Graça M Dores; Paige L Marquez; Carmen S Ng; Maria V Cano; Anuja Rastogi; Lucia Lee; John R Su; Jonathan Duffy Journal: Vaccine Date: 2021-12-07 Impact factor: 3.641
Authors: Abdulellah M Almohaya; Haya Alsubie; Bader Alqarni; Bashayer Alzayad; Ali Alghar; Khalid Alshahrani; Mazin Barry Journal: Vaccine Date: 2021-12-13 Impact factor: 3.641